Glycolysis was the first metabolic pathway elucidated, which refers to splitting one glucose molecule into two pyruvate molecules. In the presence of oxygen, pyruvate usually enters the mitochondria, where it is oxidized to acetyl-CoA, whereas in the absence of oxygen, pyruvate is reduced into lactate. The glycolysis metabolic pathway plays an important role in securing the production of energy and biomass and the maintenance of redox homeostasis. Growing evidence indicates that the dysregulation of glycolysis is associated with various diseases, including atherosclerosis, Parkinson's, type 2 diabetes, rheumatoid arthritis (RA) and cancer, etc. Therefore, further studies are needed to discover potential drugs targeting glycolysis in diseases.
Besides providing cellular energy, metabolites like 6-phosphogluconate, lactate, and pyruvate in glycolysis are also involved in regulating biological processes, such as pro-inflammatory responses in macrophage, maintaining the stemness of cancer stem cells, de-differentiation of smooth muscle cells, and so on. In addition, the many enzymes of the glycolytic pathway also play significant roles in several non-glycolytic processes, including transcriptional regulation and the phosphorylation of histones. Overall, the pathogenic regulation and the multifaceted roles of glycolytic components underscore the biological significance of glycolysis. Thus, targeting glycolysis remains attractive for therapeutic intervention. Furthermore, several preclinical studies have shown the effectiveness of this therapeutic approach, thereby supporting its scientific rationale. This Research Topic aims to discover novel drugs and therapeutic substances for the treatment and prevention of glycolysis-associated diseases. The articles within this collection will also introduce the functional roles and molecular mechanisms of medicines in disorders of glycolysis and metabolism to explore their potential therapeutic opportunities.
For this Research Topic, we welcome Original Research Articles and Reviews focused on glycolysis-associated diseases, such as atherosclerosis, Parkinson's, type 2 diabetes, rheumatoid arthritis (RA) and cancer, etc.
Potential subjects include but are not limited to the following:
• The discovery of novel molecular targets and therapeutic substances, including small molecule compounds, peptides, or other bioactive factors for the treatment of glycolysis associated diseases
• The delivery of drugs for glycolysis associated diseases
• The preventive treatments for glycolysis associated diseases
•Mechanistic studies aimed at understanding the glycolysis metabolism disorders leading to cell senescence, apoptosis, dysfunction, overgrowth, etc.
Frontiers in Experimental Pharmacology and Drug Discovery does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). This also applies to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
Glycolysis was the first metabolic pathway elucidated, which refers to splitting one glucose molecule into two pyruvate molecules. In the presence of oxygen, pyruvate usually enters the mitochondria, where it is oxidized to acetyl-CoA, whereas in the absence of oxygen, pyruvate is reduced into lactate. The glycolysis metabolic pathway plays an important role in securing the production of energy and biomass and the maintenance of redox homeostasis. Growing evidence indicates that the dysregulation of glycolysis is associated with various diseases, including atherosclerosis, Parkinson's, type 2 diabetes, rheumatoid arthritis (RA) and cancer, etc. Therefore, further studies are needed to discover potential drugs targeting glycolysis in diseases.
Besides providing cellular energy, metabolites like 6-phosphogluconate, lactate, and pyruvate in glycolysis are also involved in regulating biological processes, such as pro-inflammatory responses in macrophage, maintaining the stemness of cancer stem cells, de-differentiation of smooth muscle cells, and so on. In addition, the many enzymes of the glycolytic pathway also play significant roles in several non-glycolytic processes, including transcriptional regulation and the phosphorylation of histones. Overall, the pathogenic regulation and the multifaceted roles of glycolytic components underscore the biological significance of glycolysis. Thus, targeting glycolysis remains attractive for therapeutic intervention. Furthermore, several preclinical studies have shown the effectiveness of this therapeutic approach, thereby supporting its scientific rationale. This Research Topic aims to discover novel drugs and therapeutic substances for the treatment and prevention of glycolysis-associated diseases. The articles within this collection will also introduce the functional roles and molecular mechanisms of medicines in disorders of glycolysis and metabolism to explore their potential therapeutic opportunities.
For this Research Topic, we welcome Original Research Articles and Reviews focused on glycolysis-associated diseases, such as atherosclerosis, Parkinson's, type 2 diabetes, rheumatoid arthritis (RA) and cancer, etc.
Potential subjects include but are not limited to the following:
• The discovery of novel molecular targets and therapeutic substances, including small molecule compounds, peptides, or other bioactive factors for the treatment of glycolysis associated diseases
• The delivery of drugs for glycolysis associated diseases
• The preventive treatments for glycolysis associated diseases
•Mechanistic studies aimed at understanding the glycolysis metabolism disorders leading to cell senescence, apoptosis, dysfunction, overgrowth, etc.
Frontiers in Experimental Pharmacology and Drug Discovery does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). This also applies to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
